NEW YORK (GenomeWeb News) – BiOasis Technologies today said that it will receive cash proceeds of C$1.7 million (US$1.4 million) from the exercise of warrants that expired on March 31.

The Vancouver, BC-based developer of therapeutics and molecular diagnostics for neurological diseases said that a result of the warrants being exercised it now has cash and cash equivalents of C$2.4 million. The additional funds will enable the firm to fund a final trial of the p97 biomarker as a diagnostic for Alzheimer's disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.